The role of p53 in myelodysplastic syndromes and acute myeloid leukemia: molecular aspects and clinical implications
|
Dec 2016
|
Leuk Lymphoma
|
myelodysplastic syndromes (MDS)
|
Initial transfusion frequency and survival in myelodysplastic syndromes: hopping onto a fast train to nowhere
|
Feb 2014
|
Leuk Lymphoma
|
myelodysplastic syndromes (MDS)
|
5-Azacitidine efficacy and safety in patients aged >65 years with myelodysplastic syndromes outside clinical trials
|
Feb 2012
|
Leuk Lymphoma
|
myelodysplastic syndromes (MDS)
|
The Race for Survival in Myelodysplastic Syndromes
|
Sep 2012
|
Leuk Lymphoma
|
myelodysplastic syndromes (MDS)
|
Prognostic models in predicting outcomes in myelodysplastic syndromes after hypomethylating agent failure
|
Mar 2017
|
Leuk Lymphoma
|
myelodysplastic syndromes (MDS)
|
Prognostic relevance of cytogenetic systems in myelodysplastic syndromes.
|
Mar 2012
|
Leuk Lymphoma
|
myelodysplastic syndromes (MDS)
|
Deacetylase Inhibitors for the Treatment of Myelodysplastic Syndromes
|
Jul 2014
|
Leuk Lymphoma
|
myelodysplastic syndromes (MDS)
|
Phase I trial of SAR103168, a novel multi-kinase inhibitor,in patients with refractory/relapsed acute leukemias or high-risk myelodysplastic syndromes
|
May 2014
|
Leuk Lymphoma
|
myelodysplastic syndromes (MDS)
|
The Revised International Prognostic Scoring System (IPSS-R) is not Predictive of Survival in Patients with Secondary Myelodysplastic Syndromes
|
Apr 2015
|
Leuk Lymphoma
|
myelodysplastic syndromes (MDS)
|
ALLOGENEIC STEM CELL TRANSPLANTATION (HSCT) FOR ADULTS WITH MYELODYSPLASTIC SYNDROMES (MDS): RELEVANCE OF PRE-TRANSPLANT DISEASE STATUS.
|
Jun 2013
|
Leuk Lymphoma
|
myelodysplastic syndromes (MDS)
|